



## 余兆武 助理教授 (Stifen Yu, Assistant Prof.)

- 臺大藥學所博士
- 擁有六年業界經驗
- ✓ **藥物開發**：藥物設計合成、挑選候選藥物，完成製程放大、晶型篩選。
- ✓ **專利&技轉**：從陳基旺教授實驗室技轉到安基生技，完成專利佈局。
- ✓ **臨床試驗**：2024年藥物(AJ302) 進入Phase I Trial。  
(安基新藥AJ302 獲FDA核准進行人體臨床一期)

研究方向:新藥開發及專利申請/新化學反應開發/螢光化合物

## 表觀遺傳藥物： HDAC inhibitors

Quinazolin-2,4-dione based HDAC6 inhibitor for the treatment of NSCLC can display a synergic anticancer effect and reduce PD-L1 expression against lung cancer cells while combining with paclitaxel.



*J. Med. Chem.* **2019**, 62, 2, 857-874, Cover story

## 標的蛋白降解藥物： PROTAC Drug Design

A highly HDAC6-selective inhibitor acts as a fluorescent probe  
*Org. Biomol. Chem.*, **2018**, 16, 7820-7832, Cover story



*J. Med. Chem.* **2023**, 66, 15, 10528-10557

## 抗肺纖維化藥物： HDAC inhibitors

Discovery of HDAC6, HDAC8, and 6/8 Inhibitors and Development of Cell-Based Drug Screening Models for the Treatment of TGF- $\beta$ -Induced Idiopathic Pulmonary Fibrosis

國立臺灣大學藥學研究所

GRADUATE INSTITUTES OF PHARMACEUTICAL SCIENCES